Tirzepatide (CAS 2023788-19-2) is a 39-amino-acid synthetic dual incretin receptor agonist, or “twincretin,” that activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It is built on the native GIP sequence backbone — which confers potent GIPR activity — and further engineered with C20 fatty diacid acylation for albumin binding and Aib substitutions for DPP-IV resistance. Simultaneous dual agonism produces additive and synergistic metabolic effects: glucose-dependent insulin secretion, glucagon suppression, improved beta-cell function, delayed gastric emptying, and central satiety signaling — yielding robust glycemic and body-weight reductions beyond either single-receptor agonist. Supplied as a lyophilized powder for in vitro and preclinical research use only.

Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. The added GIP component contributes beta-cell insulin-secretory effects, insulin-sensitizing activity in adipose tissue, and glucagon modulation that GLP-1 agonism alone does not provide. In clinical trials, this dual mechanism translates to greater A1c reduction and greater body-weight loss than GLP-1 mono-agonism at comparable doses. Both peptides share the C20 fatty diacid / albumin-binding and Aib DPP-IV-resistance engineering for once-weekly duration. For researchers, tirzepatide is the reference tool to quantify the incremental contribution of GIPR agonism over GLP-1R agonism in metabolic physiology.

Tirzepatide’s extended half-life and once-weekly dosing are engineered through two structural modifications. First, a C20 eicosanedioic acid fatty diacid is conjugated to the peptide via a γ-glutamic acid (γ-Glu) spacer and an AEEA linker; this diacid binds reversibly to serum albumin, protecting the peptide from renal clearance and prolonging circulation. Second, Aib (α-aminoisobutyric acid) substitutions at key positions confer resistance to DPP-IV cleavage — the primary enzymatic degradation pathway for native incretins. Together these changes raise albumin affinity and reduce proteolysis, giving tirzepatide its extended pharmacodynamic duration compared with native GIP and GLP-1.

Store the lyophilized tirzepatide powder at -20°C in a tightly sealed, desiccated container protected from light and moisture; the lyophilized peptide is stable for the documented shelf life under these conditions. For reconstitution, use sterile, peptide-compatible aqueous buffer or dilute acetic acid at neutral to slightly acidic pH — tirzepatide is supplied as the acetate salt and is freely soluble once reconstituted. Prepare aliquots to avoid repeated freeze-thaw cycles, which degrade peptide integrity through aggregation and precipitation. Use freshly reconstituted solution promptly and keep working aliquots at 4°C for short-term use only. All handling is for research use only (RUO).

Every shipment of tirzepatide research peptide includes a full Certificate of Analysis (COA) reporting HPLC purity ≥98.0%, peptide content, endotoxin ≤1.0 EU/mg, water content, and heavy metals ≤10 ppm; a Material Safety Data Sheet (MSDS); HPLC chromatogram; mass spectrometry (MS) molecular-weight confirmation (4813.45 g/mol); and lot-specific traceability documentation. UPOR Biotech operates under ISO 9001 quality management, cGMP manufacturing practices, and FDA facility registration, ensuring reproducible batch-to-batch quality. Tirzepatide is supplied as a Research Use Only (RUO) product — not for human diagnostic or therapeutic use.